Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharma a/s - ixazomibcitrat - multipelt myelom - antineoplastiske midler - ninlaro i kombination med lenalidomid og dexamethason er indiceret til behandling af voksne patienter med multipelt myelom, der har modtaget mindst en tidligere behandling.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pensa pharma ab - eletriptanhydrobromid - filmovertrukne tabletter - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan pharmaceuticals limited - rivastigminhydrogentartrat - kapsler, hårde - 3 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan pharmaceuticals limited - rivastigminhydrogentartrat - kapsler, hårde - 4,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan pharmaceuticals limited - rivastigminhydrogentartrat - kapsler, hårde - 6 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinom, ikke-småcellet lunge - andre antineoplastiske midler, protein kinase hæmmere - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.